Eli Lilly and Company (NYSE:LLY) is Gulf International Bank UK Ltd’s 10th Largest Position

Gulf International Bank UK Ltd trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 3.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 63,877 shares of the company’s stock after selling 2,498 shares during the quarter. Eli Lilly and Company makes up about 1.5% of Gulf International Bank UK Ltd’s portfolio, making the stock its 10th biggest position. Gulf International Bank UK Ltd’s holdings in Eli Lilly and Company were worth $56,591,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. M&G Plc purchased a new position in Eli Lilly and Company during the 1st quarter worth $8,896,000. Virtu Financial LLC purchased a new stake in shares of Eli Lilly and Company during the 1st quarter worth about $2,138,000. China Universal Asset Management Co. Ltd. grew its holdings in Eli Lilly and Company by 19.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after purchasing an additional 1,620 shares during the period. Mutual Advisors LLC lifted its holdings in Eli Lilly and Company by 404.8% during the first quarter. Mutual Advisors LLC now owns 62,598 shares of the company’s stock valued at $48,699,000 after purchasing an additional 50,197 shares in the last quarter. Finally, Chesley Taft & Associates LLC boosted its holdings in Eli Lilly and Company by 5.4% in the 2nd quarter. Chesley Taft & Associates LLC now owns 22,553 shares of the company’s stock worth $20,419,000 after buying an additional 1,163 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Down 1.6 %

Eli Lilly and Company stock opened at $806.14 on Tuesday. The company has a 50 day moving average of $908.15 and a 200-day moving average of $867.39. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The stock has a market capitalization of $765.28 billion, a PE ratio of 87.15, a price-to-earnings-growth ratio of 3.09 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. During the same period last year, the company earned $0.10 EPS. The company’s revenue was up 20.4% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly and Company will post 13.23 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on LLY shares. Truist Financial lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Citigroup upped their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a report on Friday, October 25th. Guggenheim raised their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a report on Monday. Three equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,008.41.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.